Unicycive Therapeutics, Inc., (UNCY) News

Unicycive Therapeutics, Inc., (UNCY): $0.69

-0.01 (-1.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add UNCY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 485

in industry

Filter UNCY News Items

UNCY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

UNCY News Highlights

  • For UNCY, its 30 day story count is now at 2.
  • Over the past 23 days, the trend for UNCY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest UNCY News From Around the Web

Below are the latest news stories about Unicycive Therapeutics Inc that investors may wish to consider to help them evaluate UNCY as an investment opportunity.

Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two abstracts supporting the potential efficacy and safety of Renazorb (lanthanum dioxycarbonate) to be presented as posters at the National Kidney Foundation (NKF) Spring Clinical Meeting taking place April 6-10, 2022 in Boston. Renazorb is a second-generation lanthanum-based phosphate binding agent utilizing proprietary nan

Yahoo | February 2, 2022

Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

Yahoo | January 10, 2022

Unicycive Therapeutics pops 6% after receiving FDA guidance on Renazorb regulatory pathway

No summary available.

Seeking Alpha | November 29, 2021

Unicycive Therapeutics Receives FDA Guidance On Renazorb Regulatory Pathway

Unicycive Therapeutics Inc (NASDAQ: UNCY ) updated the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate). Renazorb is a second-generation lanthanum-based phosphate-binding agent utilizing proprietary nanoparticle technology for hyperphosphatemia in patients with chronic kidney disease (CKD). In a recent Type C interaction with the FDA, Unicycive sought the FDA''s feedback on the sufficiency of the Renazorb Full story available on Benzinga.com

Benzinga | November 29, 2021

Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway

LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today provided an update on the development and regulatory filing pathway for Renazorb (lanthanum

PR Newswire | November 29, 2021

Zacks Investment Research Downgrades Unicycive Therapeutics (NASDAQ:UNCY) to Sell

Unicycive Therapeutics (NASDAQ:UNCY) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a report released on Thursday, Zacks.com reports. According to Zacks, Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The companys lead drug consist Renazorb, is a []

Transcript Daily | November 20, 2021

Unicycive Therapeutics reports Q3 results

No summary available.

Seeking Alpha | November 11, 2021

Unicycive Therapeutics Announces Third Quarter 2021 Financial Results

LOS ALTOS, Calif., Nov. 11, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today reported financial results for the third quarter ended September 30, 2021. Shalabh Gupta, M.D.,

PR Newswire | November 11, 2021

Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.8%

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) rose 2.8% on Tuesday . The stock traded as high as $2.98 and last traded at $2.96. Approximately 71,110 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 569,142 shares. The stock had previously closed at $2.88. UNCY has been the subject of several []

Dakota Financial News | November 2, 2021

Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will have responsibility for Unicycive's corporate and commercial strategy and business development activities.

Yahoo | October 26, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5331 seconds.